Antidementia drug use among community-dwelling individuals with Alzheimer's disease in Finland: A nationwide register-based study

International Clinical Psychopharmacology

Volumn 29, Issue 4, 2014, Pages 216-223

  Taipale, Heidi ^a,b   Tanskanen, Antti ^c,d   Koponen, Marjaana ^a,b   Tolppanen, Anna Maija ^a,b   Tiihonen, Jari ^a,c   Hartikainen, Sirpa ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b School of Pharmacy   (Finland)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

acetylcholinesterase inhibitor; Alzheimer's disease; drug utilization; memantine; prevalence

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; NOOTROPIC AGENT; RIVASTIGMINE; AMINO ACID RECEPTOR BLOCKING AGENT; CARBAMIC ACID DERIVATIVE; INDAN DERIVATIVE; PIPERIDINE DERIVATIVE;

AGED; ALZHEIMER DISEASE; ARTICLE; COMMUNITY; DRUG USE; FEMALE; FINLAND; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; REGISTER; TREATMENT DURATION; COHORT ANALYSIS; COMPARATIVE STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG COMBINATION; DRUG MONITORING; PRACTICE GUIDELINE; PRESCRIPTION; PROPORTIONAL HAZARDS MODEL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COHORT STUDIES; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG MONITORING; DRUG PRESCRIPTIONS; DRUG THERAPY, COMBINATION; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; FINLAND; FOLLOW-UP STUDIES; GALANTAMINE; GUIDELINE ADHERENCE; HUMANS; INDANS; MALE; MEMANTINE; NOOTROPIC AGENTS; PHENYLCARBAMATES; PIPERIDINES; PRACTICE GUIDELINES AS TOPIC; PROPORTIONAL HAZARDS MODELS; REGISTRIES;

EID: 84902169598     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0000000000000032     Document Type: Article

References (46)

1. Abughosh SM, Kogut SJ (2008). Comparison of persistence rates of acetylcholine- esterase inhibitors in a state Medicaid program. Patient Prefer Adherence 2:79-85.
2. Alzheimer Association (2011). 2011 Alzheimers disease facts and figures. Alzheimers Dement 7:208-244.
3. American Psychiatric Association (1994). Diagnostic and statistical manual of mental disorders. 4th ed.Washington, DC: American Psychiatric Association.
4. Amuah JE, Hogan DB, Eliasziw M, Supina A, Beck P, Downey W, Maxwell CJ (2010). Persistence with cholinesterase inhibitor therapy in a populationbased cohort of patients with Alzheimers disease. Pharmacoepidemiol Drug Saf 19:670-679.
5. Atri A, Shaughnessy LW, Locascio JJ, Growdon JH (2008). Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 22:209-221.
6. Ballard C, Corbett A (2010). Management of neuropsychiatric symptoms in people with dementia. CNS Drugs 24:729-739.
7. Beardon PH, McGilchrist MM, McKendrick AD, McDevitt DG, MacDonald TM (1993). Primary non-compliance with prescribed medication in primary care. BMJ 307:846-848. (Pubitemid 23281752)
8. Beusterien KM, Thomas SK, Gause D, Kimel M, Arcona S, Mirski D (2004). Impact of rivastigmine use on the risk of nursing home placement in a US sample. CNS Drugs 18:1143-1148. (Pubitemid 40007496)
9. Birks J (2006). Cholinesterase inhibitors for Alzheimers disease. Cochrane Database Syst Rev 25:CD005593.
10. Brewer L, Bennett K, McGreevy C,Williams D (2013). A population-based study of dosing and persistence with anti-dementia medications. Eur J Clin Pharmacol 69:1467-1475.
11. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987). A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373-383. (Pubitemid 17055592)
12. Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, et al. (2004). Longterm donepezil treatment in 565 patients with Alzheimers disease (AD2000): randomised double-blind trial. Lancet 26:2105-2115.
13. Finnish Medical Society Duodecim, Helsinki (2010). Current care: memory disorders [in Finnish with English summary]. Available at: http://www.kay pahoito.fi [Accessed 30 August 2012].
14. Francis PT, Palmer AM, Snape M,Wilcock GK (1999). The cholinergic hypothesis of Alzheimers disease: a review of progress. J Neurol Neurosurg Psychiatry 66:137-147. (Pubitemid 29103513)
15. Fratiglioni L, Launer LJ, Andersen K, Breteler MM, Copeland JR, Dartiques JF, et al. (2000). Incidence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurology 54:S10-S15. (Pubitemid 30390599)
16. French National Authority for Health (2008). Diagnostic and management of Alzheimers disease and related disorders. Professional guidelines. Haute Autoritéde Santé. Available at: http://www.has-sante.fr. [Accessed 21 December 2013].
17. Gauthier S, Molinuevo JL (2013). Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimers disease. Alzheimers Dement 9:326-331.
18. Geldmacher DS (2003). Alzheimers disease: current pharmacotherapy in the context of patient and family needs. J Am Geriatr Soc 51:S289-S295.
19. Gill SS, Bronskill SE, Mamdani M, Sykora K, Li P, Shulman KI, et al. (2004). Representation of patients with dementia in clinical trials of donepezil. Can J Clin Pharmacol 11:e274-e285. (Pubitemid 46333124)
20. Haukka J, Suvisaari J, Tuulio-Henriksson A, Lonnqvist J (2007). High concordance between self-reported medication and official prescription database information. Eur J Clin Pharmacol 63:1069-1074. (Pubitemid 47561801)
21. Herrmann N, Gill SS, Bell CM, Anderson GM, Bronskill SE, Shulman KI, et al. (2007). A population-based study of cholinesterase inhibitor use for dementia. J Am Geriatr Soc 55:1517-1523. (Pubitemid 47508507)
22. Johnell K, Religa D, Eriksdotter M (2013). Differences in drug therapy between dementia disorders in the Swedish dementia registry: a nationwide study of over 7,000 patients. Dement Geriatr Cogn Disord 35:239-248.
23. Lachaine J, Beauchemin C, Legault M, Bincau S (2011). Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer disease. Can J Psychiatry 56:596-604.
24. Lopez OL, Becker JT, Wahed AS, Saxton RA, Wolk DA, Klunk W, Dekosky ST (2009). Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry 80:600-607.
25. Martorana A, Esposito Z, Koch G (2010). Beyond the cholinergic hypothesis: do current drugs work in Alzheimers disease? CNS Neurosci Ther 16:235-245.
26. Mauskopf JA, Paramore C, Lee WC, Snyder EH (2005). Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings. J Manag Care Pharm 11:231-251.
27. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984). Clinical diagnosis of Alzheimers disease: Report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimers disease. Neurology 34:939-944. (Pubitemid 14076461)
28. Mucha L,Wang SS, Cuffel B, McRae T, Mark TL, del Valle M (2008). Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimers disease. J Manag Care Pharm 14:451-461.
29. National Board of Health and Welfare (2010). National guidelines for care in cases of dementia. Stockholm: Socialstyrelsen.
30. National Institute for Health and Clinical Excellence (2011). NICE Technology Appraisal Guidance III: donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimers disease. Available at: http://www.nice.org.uk/nicemedia/live/13419/53619/53619.pdf. [Accessed 21 December 2013].
31. Pariente A, Pinet M, Moride Y, Merlière Y, Moore N, Fourrier-Règlat A (2010). Factors associated with persistence of cholinesterase inhibitor treatments in the elderly. Pharmacoepidemiol Drug Saf 19:680-686.
32. Porsteinsson AP, Grossberg GT, Mintzer J (2008). Memantine treatment in patients with mild to moderate Alzheimers disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 5:83-89. (Pubitemid 351536358)
33. Purhonen M, Koponen H, Tiihonen J, Tanskanen A (2012). Outcome of patients after market withdrawal of thioridazine: a retrospective analysis in a nationwide cohort. Pharmacoepidemiol Drug Saf 21:1227-1231.
34. Rikala M, Hartikainen S, Sulkava R, Korhonen MJ (2010). Validity of the Finnish Prescription Register for measuring psychotropic drug exposures among elderly Finns: a population-based intervention study. Drugs Aging 27:337-349.
35. Ritchie CW, Ames D, Clayton T, Lai R (2004). Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. Am J Geriatr Psychiatry 12:358-369. (Pubitemid 38878856)
36. Rodda J, Morgan S,Walker Z (2009). Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimers disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. Int Psychogeriatr 21: 813-824.
37. Standridge JB (2004). Pharmacotherapeutic approaches to the treatment of Alzheimers disease. Clin Ther 26:615-630.
38. Suh DC, Thomas SK, Valiyeva E, Arcona S, Vo L (2005). Drug persistency of two cholinesterase inhibitors: rivastigmine versus donepezil in elderly patients with Alzheimers disease. Drugs Aging 22:695-707. (Pubitemid 41138981)
39. Thompson S, Lanctot KL, Herrmann N (2004). The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimers disease. Expert Opin Drug Saf 3:425-440. (Pubitemid 39242717)
40. Tifratene K, Duff FL, Pradier C, Quetel J, Lafay P, Schuck S, et al. (2012). Use of drug treatments for Alzheimers disease in France: a study on a national level based on the National Alzheimers Data Bank (Banque Nationale Alzheimer). Pharmacoepidemiol Drug Saf 21:1005-1012.
41. Tiihonen J, Lönnqvist J,Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, Haukka J (2009). 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 374:620-627.
42. Tolppanen AM, Taipale H, Koponen M, Lavikainen P, Tanskanen A, Tiihonen J, Hartikainen S (2013). Use of existing data sources in clinical epidemiology: Finnish health care registers in Alzheimers disease research - the Medication use among persons with Alzheimers disease (MEDALZ- 2005) study. Clin Epidemiol 5:277-285.
43. Van den Bussche H, Kaduszkiewicz H, Koller D, Eisele M, Steinmann S, Glaeske G, Wiese B (2011). Antidementia drug prescription sources and patterns after the diagnosis of dementia in Germany: results of a claims data-based 1-year follow-up. Int Clin Psychopharmacol 26:225-231.
44. Vidal JS, Lacombe JM, Dartigues JF, Pasquier F, Robert P, Tzourio C, Alpèrovitch A (2008). Memantine therapy for Alzheimer disease in real-world practice: an observational study in a large representative sample of French patients. Alzheimer Dis Assoc Disord 22:125-130.
45. WHO Collaborating Centre for Drug Statistics Methodology (2013). The anatomical therapeutic chemical classification system. Available at: http://www.whocc.no/atc-ddd-index/. [Accessed 22 May 2013].
46. World Health Organization and Alzheimers Disease International (2012). Dementia: a public health priority. Geneva, Switzerland: World Health Organization.